PFE logoPFE
Pfizer Inc

104,944
Loading...
Loading...
News
all
press releases
Lithium Americas, Reddit, Nike, Plug Power, Pfizer: Stocks Making The Biggest Moves Today
Lithium Americas’ shares were up nearly 27% in Wednesday’s midday trade after the U.S. government confirmed that it would pick up a 5% stake in the company.
Stocktwits·1h ago
News Placeholder
More News
News Placeholder
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
Zacks·4h ago
News Placeholder
Stock Market News for Oct 1, 2025
Wall Street closed higher on Tuesday, driven by healthcare stocks.
Zacks·5h ago
News Placeholder
Eli Lilly Stock Jumps As Trump’s Drug Price Crackdown Spurs Sector Rally; Analysts Say Pfizer Deal Sets Template For Big Pharma
Analysts said the plan signals a political win that could reshape how major drugmakers engage with U.S. policymakers.
Stocktwits·17h ago
News Placeholder
Trump Announces Pfizer Drug-Pricing Deal, Company To Invest $70 Billion in US Manufacturing
The President stated that the drugs will be made available for direct purchase online through a government-operated website called TrumpRX.
Stocktwits·1d ago
News Placeholder
Trump To Announce Drug-Pricing Pact With Pfizer Later Today: Report
According to a report by The Washington Post, the deal would require Pfizer to voluntarily offer its medications through Medicaid at reduced prices.
Stocktwits·1d ago
News Placeholder
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·2d ago
News Placeholder
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Zacks·5d ago
News Placeholder
AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer
AstraZeneca and Daiichi's Enhertu wins FDA priority review in breast cancer, backed by phase III data showing a 44% lower progression risk.
Zacks·6d ago
News Placeholder
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.
Zacks·6d ago

Latest PFE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.